An in-depth look to IMMUNOVIA AB NPV operating, investing, and financing activities

0G8X free cash flow for Q3 24 is -17.35 M SEK. For 2023, 0G8X free cash flow was -147.06 M SEK and operating cash flow was -147.06 M SEK.